Organisation paid for research Program year 2025 Source: CMS Open Payments

CBCC Global Research Inc

Neither a doctor nor a teaching hospital

Research payments

$403,591

33 payments

Through program year 2025, CBCC Global Research Inc is reported as receiving $403,591 in research payments, across 33 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $44,364 6
2024 Research $5,354 1
2023 Research $860 5
2022 Research $437 1
2021 Research $268,281 3
2020 Research $67,044 11
2019 Research $17,251 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $257,491 1 payment
  2. Sanofi US Services Inc. $52,562 7 payments
  3. AbbVie, Inc. $49,448 6 payments
  4. AstraZeneca Pharmaceuticals LP $21,476 5 payments
  5. Helsinn Healthcare SA $12,475 2 payments
  6. Genentech, Inc. $7,632 4 payments
  7. MorphoSys AG $2,237 7 payments
  8. Organon LLC $270 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $257,491 1 payment
  2. A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $33,568 4 payments
  3. An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopausal and Postmenopausal Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies $18,600 2 payments
  4. M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $15,880 2 payments
  5. A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON $14,976 4 payments
  6. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer NSCLC $11,475 1 payment
  7. Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer (AMEERA-4) $10,800 1 payment
  8. Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors $10,800 1 payment
  9. A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors $10,740 2 payments
  10. Pertain Pertu Trastu Ai 1St Line Her2 MBC $7,632 4 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $270 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record